Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E-β-thalassemia): a single center study from eastern India. (se deschide o fereastră nouă)

Bohara VV, Ray S, Chakrabarti P, Ray SS, Nath UK, Chaudhuri U.

Sursă‎: Hemoglobin 2014;38(1):44-8.

Index‎: PubMed 24144212

DOI‎: 10.3109/03630269.2013.845844

https://www.ncbi.nlm.nih.gov/pubmed/24144212 (se deschide o fereastră nouă)

Hydroxyurea in thalassemia intermedia--a promising therapy. (se deschide o fereastră nouă)

Dixit A, Chatterjee TC, Mishra P, Choudhry DR, Mahapatra M, Tyagi S, Kabra M, Saxena R, Choudhry VP.

Sursă‎: Ann Hematol 2005;84(7):441-6.

Index‎: PubMed 15838670

DOI‎: 10.1007/s00277-005-1026-4

https://www.ncbi.nlm.nih.gov/pubmed/15838670 (se deschide o fereastră nouă)

Effect of hydroxyurea on the transfusion requirements in patients with severe HbE-beta-thalassaemia: a genotypic and phenotypic study. (se deschide o fereastră nouă)

Italia KY, Jijina FF, Merchant R, Panjwani S, Nadkarni AH, Sawant PM, Nair SB, Ghosh K, Colah RB.

Sursă‎: J Clin Pathol 2010;63(2):147-50.

Index‎: PubMed 20154037

DOI‎: 10.1136/jcp.2009.070391

https://www.ncbi.nlm.nih.gov/pubmed/20154037 (se deschide o fereastră nouă)

Echocardiographic finding in beta-thalassemia intermedia and major: absence of pulmonary hypertension following hydroxyurea treatment in beta-thalassemia intermedia. (se deschide o fereastră nouă)

Karimi M, Borzouee M, Mehrabani A, Cohan N.

Sursă‎: Eur J Haematol 2009;82(3):213-8.

Index‎: PubMed 19077048

DOI‎: 10.1111/j.1600-0609.2008.01192.x

https://www.ncbi.nlm.nih.gov/pubmed/19077048 (se deschide o fereastră nouă)

Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. (se deschide o fereastră nouă)

Karimi M, Mohammadi F, Behmanesh F, Samani SM, Borzouee M, Amoozgar H, Haghpanah S.

Sursă‎: Eur J Haematol 2010;84(1):52-8.

Index‎: PubMed 19799627

DOI‎: 10.1111/j.1600-0609.2009.01356.x

https://www.ncbi.nlm.nih.gov/pubmed/19799627 (se deschide o fereastră nouă)

Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece. (se deschide o fereastră nouă)

Loukopoulos D, Voskaridou E, Kalotychou V, Schina M, Loutradi A, Theodoropoulos I.

Sursă‎: Blood Cells Mol Dis 2000;26(5):453-66.

Index‎: PubMed 11112383

DOI‎: 10.1006/bcmd.2000.0328

https://www.ncbi.nlm.nih.gov/pubmed/11112383 (se deschide o fereastră nouă)

Fetal globin stimulant therapies in the beta-hemoglobinopathies: principles and current potential. (se deschide o fereastră nouă)

Perrine SP.

Sursă‎: Pediatr Ann 2008;37(5):339-46.

Index‎: PubMed 18543545

https://www.ncbi.nlm.nih.gov/pubmed/18543545 (se deschide o fereastră nouă)

Single and combination drug therapy for fetal hemoglobin augmentation in hemoglobin E-beta 0-thalassemia: Considerations for treatment. (se deschide o fereastră nouă)

Singer ST, Kuypers FA, Olivieri NF, Weatherall DJ, Mignacca R, Coates TD, Davies S, Sweeters N, Vichinsky EP.

Sursă‎: Ann N Y Acad Sci 2005;1054:250-6.

Index‎: PubMed 16339672

DOI‎: 10.1196/annals.1345.031

https://www.ncbi.nlm.nih.gov/pubmed/16339672 (se deschide o fereastră nouă)

Treatment of beta-thalassemia patients with recombinant human erythropoietin: effect on transfusion requirements and soluble adhesion molecules. (se deschide o fereastră nouă)

Chaidos A, Makis A, Hatzimichael E, Tsiara S, Gouva M, Tzouvara E, Bourantas KL.

Sursă‎: Acta Haematol 2004;111(4):189-95.

Index‎: PubMed 15153710

DOI‎: 10.1159/000077551

https://www.ncbi.nlm.nih.gov/pubmed/15153710 (se deschide o fereastră nouă)

Efficacy of erythropoietin on dialysis in patients with beta thalassemia minor. (se deschide o fereastră nouă)

Di Iorio B, De Nicola L, Bellizzi V, Minutolo R, Zamboli P, Rubino R, Fuiano G, Conte G.

Sursă‎: Blood Purif 2004;22(5):453-60.

Index‎: PubMed 15359104

DOI‎: 10.1159/000080729

https://www.ncbi.nlm.nih.gov/pubmed/15359104 (se deschide o fereastră nouă)

The role of recombinant human erythropoietin in the treatment of thalassemia. (se deschide o fereastră nouă)

Rachmilewitz EA, Aker M.

Sursă‎: Ann N Y Acad Sci 1998;850:129-38.

Index‎: PubMed 9668535

https://www.ncbi.nlm.nih.gov/pubmed/9668535 (se deschide o fereastră nouă)

Darbepoetin alfa for the treatment of anaemia in alpha- or beta- thalassaemia intermedia syndromes. (se deschide o fereastră nouă)

Singer ST, Vichinsky EP, Sweeters N, Rachmilewitz E.

Sursă‎: Br J Haematol 2011;154(2):281-4.

Index‎: PubMed 21496003

DOI‎: 10.1111/j.1365-2141.2011.08617.x

https://www.ncbi.nlm.nih.gov/pubmed/21496003 (se deschide o fereastră nouă)

The emerging role of fetal hemoglobin induction in non-transfusion-dependent thalassemia. (se deschide o fereastră nouă)

Thein SL.

Sursă‎: Blood Rev 2012;26 Suppl 1:S35-9.

Index‎: PubMed 22631042

DOI‎: 10.1016/S0268-960X(12)70011-5

https://www.ncbi.nlm.nih.gov/pubmed/22631042 (se deschide o fereastră nouă)